This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, A. C.
Right arrow Articles by Collins, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, A. C.
Right arrow Articles by Collins, P. L.

 Previous Article  |  Next Article 

Journal of Virology, February 2002, p. 1089-1099, Vol. 76, No. 3
0022-538X/01/$04.00+0     DOI: 10.1128/JVI.76.3.1089-1099.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone

Alexander C. Schmidt,1* Daniel R. Wenzke,1 Josephine M. McAuliffe,1 Marisa St. Claire,2 William R. Elkins,3 Brian R. Murphy,1 and Peter L. Collins1

Laboratory of Infectious Diseases,1 Bioqual, Inc., Rockville, Maryland 20850,2 Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 208923

Received 28 June 2001/ Accepted 19 October 2001

Reverse genetics was used to develop a two-component, trivalent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncytial virus (RSV) subgroups A and B. The backbone for each of the two components of this vaccine was the attenuated recombinant bovine/human PIV3 (rB/HPIV3), a recombinant BPIV3 in which the bovine HN and F protective antigens are replaced by their HPIV3 counterparts (48). This chimera retains the well-characterized host range attenuation phenotype of BPIV3, which appears to be appropriate for immunization of young infants. The open reading frames (ORFs) for the G and F major protective antigens of RSV subgroup A and B were each placed under the control of PIV3 transcription signals and inserted individually or in homologous pairs as supernumerary genes in the promoter proximal position of rB/HPIV3. The level of replication of rB/HPIV3-RSV chimeric viruses in the respiratory tract of rhesus monkeys was similar to that of their parent virus rB/HPIV3, and each of the chimeras induced a robust immune response to both RSV and HPIV3. RSV-neutralizing antibody titers induced by rB/HPIV3-RSV chimeric viruses were equivalent to those induced by infection with wild-type RSV, and HPIV3-specific antibody responses were similar to, or slightly less than, after infection with the rB/HPIV3 vector itself. This study describes a novel vaccine strategy against RSV in which vaccine viruses with a common attenuated backbone, specifically rB/HPIV3 derivatives expressing the G and/or F major protective antigens of RSV subgroup A and of RSV subgroup B, are used to immunize by the intranasal route against RSV and HPIV3, which are the first and second most important viral agents of pediatric respiratory tract disease worldwide.

* Corresponding author. Mailing address: LID, NIAID, NIH, Bldg. 7, Rm. 130, 7 Center Dr. MSC 0720, Bethesda, MD 20892. Phone: (301) 496-3490. Fax: (301) 496-8312. E-mail: aschmidt{at}niaid.nih.gov.

Journal of Virology, February 2002, p. 1089-1099, Vol. 76, No. 3
0022-538X/01/$04.00+0     DOI: 10.1128/JVI.76.3.1089-1099.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • del Valle, J. R., Devaux, P., Hodge, G., Wegner, N. J., McChesney, M. B., Cattaneo, R. (2007). A Vectored Measles Virus Induces Hepatitis B Surface Antigen Antibodies While Protecting Macaques against Measles Virus Challenge. J. Virol. 81: 10597-10605 [Abstract] [Full Text]  
  • Bukreyev, A., Skiadopoulos, M. H., Murphy, B. R., Collins, P. L. (2006). Nonsegmented negative-strand viruses as vaccine vectors.. J. Virol. 80: 10293-10306 [Full Text]  
  • Bukreyev, A., Huang, Z., Yang, L., Elankumaran, S., St. Claire, M., Murphy, B. R., Samal, S. K., Collins, P. L. (2005). Recombinant Newcastle Disease Virus Expressing a Foreign Viral Antigen Is Attenuated and Highly Immunogenic in Primates. J. Virol. 79: 13275-13284 [Abstract] [Full Text]  
  • Collins, P. L., Murphy, B. R. (2005). New Generation Live Vaccines against Human Respiratory Syncytial Virus Designed by Reverse Genetics. Proc Am Thorac Soc 2: 166-173 [Abstract] [Full Text]  
  • Baron, M. D., Banyard, A. C., Parida, S., Barrett, T. (2005). The Plowright vaccine strain of Rinderpest virus has attenuating mutations in most genes. J. Gen. Virol. 86: 1093-1101 [Abstract] [Full Text]  
  • Roberts, A., Vogel, L., Guarner, J., Hayes, N., Murphy, B., Zaki, S., Subbarao, K. (2005). Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters. J. Virol. 79: 503-511 [Abstract] [Full Text]  
  • Tang, R. S., MacPhail, M., Schickli, J. H., Kaur, J., Robinson, C. L., Lawlor, H. A., Guzzetta, J. M., Spaete, R. R., Haller, A. A. (2004). Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys. J. Virol. 78: 11198-11207 [Abstract] [Full Text]  
  • Buchholz, U. J., Bukreyev, A., Yang, L., Lamirande, E. W., Murphy, B. R., Subbarao, K., Collins, P. L. (2004). Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 101: 9804-9809 [Abstract] [Full Text]  
  • Newman, J. T., Riggs, J. M., Surman, S. R., McAuliffe, J. M., Mulaikal, T. A., Collins, P. L., Murphy, B. R., Skiadopoulos, M. H. (2004). Generation of Recombinant Human Parainfluenza Virus Type 1 Vaccine Candidates by Importation of Temperature-Sensitive and Attenuating Mutations from Heterologous Paramyxoviruses. J. Virol. 78: 2017-2028 [Abstract] [Full Text]  
  • Guillaume, V., Contamin, H., Loth, P., Georges-Courbot, M.-C., Lefeuvre, A., Marianneau, P., Chua, K. B., Lam, S. K., Buckland, R., Deubel, V., Wild, T. F. (2004). Nipah Virus: Vaccination and Passive Protection Studies in a Hamster Model. J. Virol. 78: 834-840 [Abstract] [Full Text]  
  • Tang, R. S., Schickli, J. H., MacPhail, M., Fernandes, F., Bicha, L., Spaete, J., Fouchier, R. A. M., Osterhaus, A. D. M. E., Spaete, R., Haller, A. A. (2003). Effects of Human Metapneumovirus and Respiratory Syncytial Virus Antigen Insertion in Two 3' Proximal Genome Positions of Bovine/Human Parainfluenza Virus Type 3 on Virus Replication and Immunogenicity. J. Virol. 77: 10819-10828 [Abstract] [Full Text]  
  • Haller, A. A., Mitiku, M., MacPhail, M. (2003). Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. J. Gen. Virol. 84: 2153-2162 [Abstract] [Full Text]  
  • Bukreyev, A., Skiadopoulos, M. H., McAuliffe, J., Murphy, B. R., Collins, P. L., Schmidt, A. C. (2002). More antibody with less antigen: Can immunogenicity of attenuated live virus vaccines be improved?. Proc. Natl. Acad. Sci. USA 99: 16987-16991 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»